ArticleDiagnostics (Basel, Switzerland)2020

Rituximab Plus Chemotherapy Provides No Clinical Benefit in a Peripheral T-Cell Lymphoma Not Otherwise Specified with Aberrant Expression of CD20 and CD79a: A Case Report and Review of the Literature.

Alessandro Mangogna et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.